ArticleWorld journal of orthopedics2025
Osteoporosis and fragility fractures in patients with acromegaly: A two-center cross-sectional study.
Article in World journal of orthopedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcromegaly, a disease of excess growth hormone, is known to alter bone structure and increase the risk of osteoporosis and fractures. This study aimed to assess the prevalence of vertebral, non-vertebral, and hip fragility fractures, as well as osteoporosis, in a cohort of patients with acromegaly.
aimTo assess the prevalence of vertebral fragility fractures, non-vertebral fragility fractures, hip fragility fractures, and osteoporosis in patients diagnosed with acromegaly.
methodsData were collected on age, sex, body mass index (BMI), time from diagnosis of acromegaly, insulin-like growth factor (IGF-1) levels, disease control, pharmacological management, risk factors for osteoporosis, vertebral fragility fractures, non-vertebral fragility fractures, hip fragility fractures, and osteoporosis.
resultsA total of 124 patients with acromegaly were included (67 men and 57 women). The mean age at diagnosis was 44 ± 12 years; the mean time from diagnosis was 12 ± 8 years; and the mean BMI was 27 ± 4 kg/m². Fragility fractures were found in 27 patients (21%). There were no significant differences in the presence of osteoporosis or fragility fractures according to age, sex, BMI, duration of acromegaly, or IGF-1 levels at diagnosis. A higher percentage of patients with osteoporosis were treated with somatostatin analogs compared to those without osteoporosis (46%
conclusionA high prevalence of osteoporosis and fragility fractures was found in patients with acromegaly, regardless of age, sex, BMI, time from diagnosis, IGF-1 levels, and disease control. More patients with osteoporosis were treated with somatostatin analogs compared to those without osteoporosis. Taken together, our results suggest that the severity of the disease and the need for second-line therapies, may be associated with the increased risk of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.